10:03 AM EDT, 03/09/2026 (MT Newswires) -- Lyell Immunopharma ( LYEL ) said Monday it appointed Smital Shah as chief financial and business officer, effective immediately, and closed an additional $50 million tranche of its July 2025 private placement.

Shah most recently served as independent CFO and chief business officer consultant to various companies, Lyell said.

The company said the $50 million private placement was completed after a clinical milestone was achieved for rondecabtagene autoleucel in patients with relapsed/refractory large B-cell lymphoma.

The closing of the additional tranche brings the total private placement proceeds to about $100 million, and Lyell said it now expects its cash, cash equivalents and marketable securities to fund operations into Q2 of 2027.

Shares of Lyell were up 4.4% in mid-morning trading Monday.

Price: 23.45, Change: +0.99, Percent Change: +4.41